Bayer has achieved a significant milestone with its drug Asundexian, which has successfully completed the Phase-III OCEANIC-STROKE trial, meeting both efficacy and safety endpoints. The FXIa inhibitor, administered once daily, significantly reduced the risk of recurrent ischemic strokes in over 12,300 patients without increasing the rate of severe bleeding. This marks a major advancement in secondary stroke prevention, addressing a critical gap where current anticoagulants often pose bleeding risks. Bayer plans to prepare for regulatory approval swiftly. The positive data revives hopes for Asundexian, which was previously considered a weaker candidate after a setback in atrial fibrillation indications. Market analysts now see a peak sales potential of around 2 to 4 billion euros, depending on market access and indications, with long-term prospects remaining open for future expansion. The drug's success could reposition Bayer as a key player in the growing anticoagulant market, driven by demographic trends and cardiovascular risks. The company's stock is expected to rise on this news, reflecting renewed investor confidence. Meanwhile, Bayer's overall financial outlook shows some improvement, with a slightly better-than-expected forecast for EBITDA before special effects, and ongoing discussions about dividend policies and legal challenges.